Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

NCT06358573 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer
TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: INT230-6
OTHER: neoadjuvant immuno-chemotherapy

Sponsor

Swiss Cancer Institute